mKIAA0195 (Transmembrane Protein 94) Activators encompass a diverse range of chemical compounds that enhance its functional activity through various signaling pathways. Forskolin, by increasing intracellular cAMP levels, activates PKA, which then phosphorylates substrates potentially interacting with mKIAA0195, facilitating its function related to membrane processes. Concurrently, Ionomycin elevates intracellular calcium levels, thereby influencing calcium-dependent signaling pathways crucial for mKIAA0195's membrane-associated activities. This elevation in calcium signaling, similar to the effects induced by Thapsigargin, which inhibits SERCA leading to increased intracellular calcium, potentially enhances mKIAA0195's role in the cell. Phorbol 12-myristate 13-acetate (PMA) and Bisindolylmaleimide I exert their effects through modulating Protein Kinase C (PKC) activity. PMA, as a PKC activator, and Bisindolylmaleimide I, a PKC inhibitor, create a dynamic environment in PKC-mediated signaling that intersects with mKIAA0195's function, thereby modulating its activity in the cell membrane context.
Furthermore, the mKIAA0195 activity is influenced by compounds that alter the MAPK signaling cascade. SB203580, a p38 MAPK inhibitor, and U0126, a MEK1/2 inhibitor, shift cellular signaling dynamics, potentially favoring pathways where mKIAA0195 plays a role, thus enhancing its function. LY294002 and Rapamycin, targeting PI3K/Akt and mTOR pathways respectively, contribute to the nuanced regulation of mKIAA0195 by altering the broader signaling landscape in which this protein operates. Epigallocatechin Gallate (EGCG), known for its kinase inhibitory properties, and Sphingosine-1-phosphate, a modulator of lipid signaling, further contribute to this regulatory network. These compounds, through their targeted effects on cellular signaling, facilitate the enhancement of mKIAA0195's functions related to membrane processes without necessitating direct activation or upregulation of the protein itself, thereby highlighting the complexity and interconnected nature of cellular signaling pathways in regulating protein activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin, a calcium ionophore, increases intracellular calcium levels, potentially affecting mKIAA0195 by altering calcium-dependent signaling pathways that are crucial for its membrane-associated activities. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates Protein Kinase C (PKC), which can phosphorylate proteins that interact with or modify the activity of mKIAA0195, thus enhancing its function in the membrane. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
This PKC inhibitor can indirectly enhance mKIAA0195 activity by modulating PKC-mediated signaling pathways, which may include regulatory mechanisms that intersect with mKIAA0195 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK, potentially altering signaling pathways that intersect with mKIAA0195 function, leading to its enhanced activity in cellular processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2 in the MAPK pathway. This inhibition can shift cellular signaling dynamics in a way that favors pathways involving mKIAA0195, potentially enhancing its functional role in the cell. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
As a PI3K inhibitor, LY294002 modulates PI3K/Akt signaling, which could lead to the enhancement of mKIAA0195's activity due to changes in downstream signaling pathways that intersect with mKIAA0195's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can lead to altered cellular signaling that indirectly enhances mKIAA0195 activity, particularly in pathways associated with cell growth and survival where mKIAA0195 might be involved. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG, a kinase inhibitor, can modulate various signaling pathways. Its action could indirectly enhance mKIAA0195 activity by affecting signaling pathways that are crucial for mKIAA0195's role in the membrane. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
This compound modulates lipid signaling pathways, potentially influencing mKIAA0195 activity by altering membrane dynamics or signaling pathways related to membrane-associated functions where mKIAA0195 is involved. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin increases intracellular calcium by inhibiting the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), potentially enhancing mKIAA0195 activity through calcium-dependent signaling pathways. | ||||||